Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME study of Catadegbrutinib in healthy males
NCT06776679Phase 1Completed
- Sponsor
- BeiGene
- Start
- Jan 2025
- Primary completion
- Mar 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of catadegbrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL) and 4 more, sponsored by BeiGene. Primary endpoints: Total Radioactivity Recovery (fet1-t2) in Urine and Feces at 35 days, Area Under the Plasma Concentration-time Curve from Time 0 Extrapolated to Infinity (AUC0-∞) of BGB-16673 at 35 days and 12 more. Started Jan 2025; status: completed.
02
Drugs
catadegbrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)Waldenström macroglobulinemia (WM)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT06776679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06776679.